NANPING, China , Feb. 19, 2025 /PRNewswire/ -- Golden Heaven Group Holdings Ltd. ("Golden Heaven" or the "Company") (Nasdaq: GDHG), an amusement park operator in China, today announced that Nanping Golden Heaven Amusement Park Management Co., Ltd.

INDIANAPOLIS , Feb. 19, 2025 /PRNewswire/ -- Corteva, Inc. (NYSE: CTVA) announces that Chief Executive Officer, Chuck Magro, and Executive Vice President and Chief Financial Officer, David Johnson, will speak at the 2025 Bank of America Global Agriculture & Materials conference at 9:00 a.m. Eastern Time on Wednesday, February 26, 2025.

Devon Energy: Oversold And On Sale Or A Value Trap? (Technical Analysis)

STATEN ISLAND, N.Y. , Feb. 19, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Japanese Patent Office (JPO) in January 2025.

HAIFA, Israel , Feb. 19, 2025 /PRNewswire/ -- ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) announced today that the Company will release its fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025, before the U.S. financial markets open.

MARLBOROUGH, Mass. , Feb. 19, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025.

WALTHAM, Mass. , Feb. 19, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced a poster presentation at the 20th Congress of the European Crohn's and Colitis Organisation (ECCO), held February 19-22, 2025, in Berlin, Germany, showing that combined inhibition of α4β7 integrin and TL1A cytokine is superior to either monotherapy in mouse models of colitis and coadministration demonstrates no drug-drug effects on exposure in non-human primates (NHPs).

EVANSVILLE, Ind. , Feb. 19, 2025 /PRNewswire/ -- Escalade, Inc. (NASDAQ: ESCA, or the "Company"), a leading manufacturer and distributor of sporting goods and indoor/outdoor recreational equipment, today announced that it will issue fourth quarter and full year 2024 results before the market opens on Wednesday, February 26, 2025.

New Tables Capability Transforms Research Data into Structured Insights for More Efficient Literature Analysis HENDERSON, Nev. , Feb. 19, 2025 /PRNewswire/ -- Research Solutions (NASDAQ: RSSS), a leader in AI solutions built for researchers, announced the launch of Tables in Scite Assistant, a significant advancement in research capabilities that helps researchers automatically extract and analyze data from scientific literature.

SANTA BARBARA, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Public safety advocacy group The Dawn Project has revealed the findings of its safety tests of Tesla Full Self-Driving version 13. The tests reveal that Full Self-Driving will illegally blow past stopped school buses with their stop signs extended and red lights flashing, and will run down a child crossing the road in front of the bus.

ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering global alternative asset manager specializing in leveraging longevity data and actuarial technology to offer uncorrelated investment opportunities, today announces the rebranding of FCF Advisors to Abacus FCF Advisors, a subsidiary of ABL Wealth.

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your Crocs, Inc. (NASDAQ:CROX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/crocs-inc-lawsuit-submission-form?prid=130506&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Canopy Growth Corporation ("Canopy Growth") (NASDAQ:CGC) concerning possible violations of federal securities laws. On February 7, 2025, Canopy issued a press release on the Company's financial results for the third quarter of its fiscal year 2025.

EMERYVILLE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings.

TAMPA, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- LM Funding America, Inc. (NASDAQ:LMFA) (“LM Funding” or the “Company”), a Bitcoin mining and technology-based specialty finance company, today announced a strategic partnership between its US Digital Mining and Hosting Co subsidiary (“USDM”) and Luxor Technology Corporation (“Luxor”), a leader in Bitcoin mining software services, for the deployment of LuxOS firmware on the Company's Bitcoin mining fleet.

Shenzhen, China, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Top KingWin Ltd (“Top KingWin” or the "Company") (Nasdaq: WAI) today announced that on February 18, 2025, it entered into a securities purchase agreement (the “SPA”) to issue a convertible note in the original principal amount of $1,000,000 (the “Note”) to an institutional investor (the “Purchaser”), convertible into its class A ordinary shares, par value of $0.0001 per share (the “Ordinary Shares”), for gross proceeds of $900,000 (the “Offering”). R.F. Lafferty & Co., Inc. acted as the Company's exclusive placement agent for this Offering.

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Nixxy, Inc, (NASDAQ:NIXX), or "Nixxy" or the "Company," today announced it has withdrawn a proposed private offering of up to $50 million aggregate principal amount of Bitcoin-based, zero-coupon convertible notes. The Company continues to evaluate its financing options, however the Board has determined that with Nixxy's current significant progress in its acquisition strategy, combined with less than favorable market conditions, such financing is no longer in the shareholders' best interest.

Rodney (Rod) Blakestad Leo J. Jackson "The Critical Minerals and ZEO Company" DALLAS, TX / ACCESS Newswire / February 19, 2025 / United States Antimony Corporation ("USAC", or the "Company"), (NYSE:UAMY) announced today the appointment of two new Vice Presidents of the Company in different divisions.

SANTA ANA, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that Anita Fletcher, M.D. has been appointed as the National Principal Investigator (“PI”) for its Phase 2a clinical trial of troculeucel, expanded enhanced autologous NK cell therapy, for the treatment of moderate Alzheimer's disease (NCT06189963). In addition to Dr. Fletcher's appointment as National PI, NKGen is pleased to announce AdventHealth Research Institute, Neuroscience Research in Orlando will be the first …

NASHUA, N.H., Feb. 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced that five clinical presentations and abstracts highlighting the Company's advancements in breast cancer detection, risk evaluation, and breast arterial calcification (BAC) assessment have been accepted for presentation at the European Congress of Radiology (ECR) 2025, which will take place from February 26 to March 2, 2025, in Vienna, Austria.